Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
Recruiting
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
07/08/2025
Locations: UT Southwestern Medical Center / Children's Medical Center, Dallas, Texas
Conditions: Deep Venous Thrombosis, Pulmonary Embolism
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Nantz National Alzheimer Center Houston, Houston, Texas
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Recruiting
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Cullinan Investigative Site, Plano, Texas
Conditions: Sjögren, Sjogren Disease, Sjogren's Syndrome
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Recruiting
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: Tekton Research, LLC, Austin, Texas
Conditions: Sjogren Disease
Improving Behavioral Health for Caregivers and Children After Pediatric Injury
Recruiting
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This propos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Children's Memorial Hermann Hospital, Houston, Texas
Conditions: Quality of Life, PTSD, Depression Not Otherwise Specified, Child Externalizing Behavior
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
Recruiting
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Local Institution - 0102, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Recruiting
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Texas M. D. Anderson Cancer Center - Partner, Houston, Texas
Conditions: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/07/2025
Locations: University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Conditions: Treatment Resistant Depression
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Recruiting
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/07/2025
Locations: Clinical Site, Fort Worth, Texas
Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Intelligent Optical Probe for Guiding Core Needle Biopsy Procedures
Recruiting
To learn if an investigational imaging device can help to identify tumor tissue before a biopsy is taken.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Needle Biopsy
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: The Univeristy of Texas Md Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen